ArticleCommunications engineering2025
An engineered culture vessel and flow system to improve the in vitro analysis of volatile organic compounds.
Article in Communications engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Volatile organic compounds (VOCs) are a biologically important subset of an organism's metabolome, yet in vitro techniques for the analysis of these small molecules vary substantially in practice, restricting the interpretation of study findings. Here, we present an engineered culture tool, termed the "Biodome", designed to enhance endogenous analyte recovery by integrating dynamic headspace sampling methodology for the recovery of VOCs from biological cultures. We validate the functionality of the device for in vitro volatile metabolomics utilizing computational modeling and fluorescent imaging of mammalian cell culture. Leveraging comprehensive two-dimensional gas chromatography coupled with a time-of-flight mass spectrometer and the enhanced sampling capabilities afforded by our tool, we identify 14 statistically significant VOCs not found in the media or exogenously derived from the sampling method, four of which have not been previously reported in vitro. To demonstrate applicability beyond mammalian cell culture, we assess the production of VOCs throughout the log and stationary phases of growth in ampicillin-resistant DH5α Escherichia coli. We identified 19 compounds with results supporting endogenous production, two of which had not previously associated with E. coli, 3-Octanone and 3-Tridecanone. Our findings emphasize the improved capabilities of the Biodome for in vitro volatile metabolomics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.